Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A hardening of the kidney glomerulus caused by scarring of the blood vessels.
Biomarker and diagnostic research for glomerulosclerosis has been reported in the published literature.
33 clinical trials registered, 26 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 1 PHASE4, 2 PHASE3, 8 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07220083](https://clinicaltrials.gov/study/NCT07220083) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:52 PM UTC
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) |
PHASE3 |
Boehringer Ingelheim |
RECRUITING |
[NCT05650619](https://clinicaltrials.gov/study/NCT05650619) | Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease | — | University of Michigan | RECRUITING |
[NCT05003986](https://clinicaltrials.gov/study/NCT05003986) | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | PHASE2 | Travere Therapeutics, Inc. | RECRUITING |
[NCT06090227](https://clinicaltrials.gov/study/NCT06090227) | AMPK-activation by Metformin in FSGS: AMP-FSGS | PHASE1 | Yale University | RECRUITING |
[NCT04571658](https://clinicaltrials.gov/study/NCT04571658) | NEPTUNE Match Study | NA | University of Michigan | RECRUITING |
283 publications have been identified in PubMed for glomerulosclerosis. Research spans Basic Science / Preclinical (28%), Review / Meta-Analysis (24%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 67 | 28% |
Research summaries | 58 | 24% |
Disease patterns and progression | 36 | 15% |
Clinical study results | 28 | 12% |
Patient case studies | 16 | 7% |
Testing and diagnosis research | 15 | 6% |
New treatment approaches | 11 | 5% |
Other research | 6 | 3% |
Schmidt J (2026). [PMID: 41910486](https://pubmed.ncbi.nlm.nih.gov/41910486/). *Kidney360*. [Gene Therapy / Novel Therapeutics]
Wongboonsin J (2026). [PMID: 41453490](https://pubmed.ncbi.nlm.nih.gov/41453490/). *Kidney Int*. [Gene Therapy / Novel Therapeutics]
Mashayekhi M (2026). [PMID: 41410808](https://pubmed.ncbi.nlm.nih.gov/41410808/). *Clin Exp Nephrol*. [Review / Meta-Analysis]
Laslandes M (2026). [PMID: 41360256](https://pubmed.ncbi.nlm.nih.gov/41360256/). *Am J Kidney Dis*. [Epidemiology / Natural History]
Zhu F (2026). [PMID: 41417662](https://pubmed.ncbi.nlm.nih.gov/41417662/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Hamatani H (2026). [PMID: 41545031](https://pubmed.ncbi.nlm.nih.gov/41545031/). *Am J Physiol Renal Physiol*. [Basic Science / Preclinical]
Bigatti C (2026). [PMID: 42000953](https://pubmed.ncbi.nlm.nih.gov/42000953/). *Pediatr Nephrol*. [Review / Meta-Analysis]
Vivarelli M (2026). [PMID: 41616796](https://pubmed.ncbi.nlm.nih.gov/41616796/). *Lancet*. [Epidemiology / Natural History]
Patel CA (2026). [PMID: 40719843](https://pubmed.ncbi.nlm.nih.gov/40719843/). *Pharmacol Rep*. [Review / Meta-Analysis]
Rout P (2026). [PMID: 30335305](https://pubmed.ncbi.nlm.nih.gov/30335305/). *Unknown Journal*. [Review / Meta-Analysis]